Belite Bio, Inc (BLTE)
| Market Cap | 6.09B +216.7% |
| Revenue (ttm) | n/a |
| Net Income | -77.61M |
| EPS | -2.31 |
| Shares Out | 39.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,969 |
| Open | 156.50 |
| Previous Close | 156.00 |
| Day's Range | 152.53 - 156.99 |
| 52-Week Range | 56.10 - 200.00 |
| Beta | -1.19 |
| Analysts | Strong Buy |
| Price Target | 198.00 (+27.84%) |
| Earnings Date | May 22, 2026 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $198.0, which is an increase of 27.84% from the latest price.
News
Belite Bio management to meet wit Cantor
Breakfast Meeting to be held in Denver on May 5 hosted by Cantor.
Belite Bio Transcript: Deutsche Bank ADR Virtual Investor Conference
Tinlarebant, an oral therapy for Stargardt disease, achieved a 36% reduction in lesion growth and sustained 80% RBP4 reduction in phase III trials, with strong safety and regulatory progress. The therapy addresses a major unmet need and is positioned for broad application in retinal diseases.
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical stage development company based in San Diego and focused on advancing novel therapeutics targeting degenerative ...
Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant
Belite Bio (BLTE) announced that it has initiated a rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for tinlarebant, an investigational novel
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that ...
Belite Bio Transcript: Leerink Global Healthcare Conference 2026
Tinlarebant, an oral RBP4 antagonist, showed a 36% reduction in Stargardt disease progression in a global phase III trial, with strong safety and efficacy in both eyes. U.S. and global regulatory filings are underway, and commercialization plans focus on genetic testing and market readiness.
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $200 from $185 and keeps a Buy rating on the shares following the Q4 report. The Phase 3
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a
Belite Bio price target raised to $217 from $187 at Benchmark
Benchmark raised the firm’s price target on Belite Bio (BLTE) to $217 from $187 and keeps a Buy rating on the shares. The company “achieved a major catalyst” during Q4
Belite Bio price target raised to $201 from $191 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $201 from $191 and keeps an Overweight rating on the shares. The company’s Q4 update
Belite Bio price target raised to $200 from $195 at BofA
BofA raised the firm’s price target on Belite Bio (BLTE) to $200 from $195 and keeps a Buy rating on the shares. After the company reported FY25 results and provided
Belite Bio Earnings Call Transcript: Q4 2025
Key 2025 milestones included positive phase III results for Stargardt disease, strong fundraising, and a robust cash position. NDA submission is planned for Q2 2026, with commercialization targeted for Q1 2027 and significant investments in launch preparation.
Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)
“2025 marked a defining year for Belite, highlighted by positive topline results from our pivotal Phase 3 DRAGON trial, establishing tinlarebant as a potential first-in-class therapy for Stargardt dis...
Belite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
06:11 EST Belite Bio (BLTE) sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio price target raised to $223 from $194 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $223 from $194 and keeps an Outperform rating on the shares.
Belite Bio completes enrollment in DRAGON II trial of tinlarebant
Belite Bio (BLTE) announced the completion of enrollment of 60 subjects, including 15 Japanese subjects, in the Phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt
Belite Bio initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Belite Bio (BLTE) with a Buy rating and $195 price target Tinlarebant is an oral, once-daily RPB4 antagonist that has produced positive Phase
Belite Bio initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Belite Bio (BLTE) with an Overweight rating and $191 price target The firm says its key opinion leader checks support a multi-billion dollar opportunity for
Belite Bio participates in a conference call with H.C. Wainwright
Healthcare Analyst Yi Chen, along with Chief Medical Officer Scholl discuss the company’s reported data from the Phase 3 DRAGON trial of Tinlarebant in adolescent patients with Stargardt disease on
Belite Bio price target raised to $200 from $140 at Maxim
Maxim raised the firm’s price target on Belite Bio (BLTE) to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from
Belite Bio 2.273M share Spot Secondary priced at $154.00
The deal range was $150.00-$154.00. Morgan Stanley, Leerink, BofA and Cantor Fitzgerald acted as joint book running managers for the offering.
Mizuho upgrades Belite to Buy on ‘impressive’ Stargardt data
Mizuho analyst Graig Suvannavejh upgraded Belite Bio (BLTE) to Outperform from Neutral with a price target of $194, up from $105. The firm cites the positive Phase 3 data for
Belite Bio upgraded to Outperform from Neutral at Mizuho
Mizuho analyst Graig Suvannavejh upgraded Belite Bio (BLTE) to Outperform from Neutral with a $194 price target
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...